Cargando…
NKG2D receptor activation drives primary graft dysfunction severity and poor lung transplantation outcomes
Clinical outcomes after lung transplantation, a life-saving therapy for patients with end-stage lung diseases, are limited by primary graft dysfunction (PGD). PGD is an early form of acute lung injury with no specific pharmacologic therapies. Here, we present a large multicenter study of plasma and...
Autores principales: | Calabrese, Daniel R., Tsao, Tasha, Magnen, Mélia, Valet, Colin, Gao, Ying, Mallavia, Beñat, Tian, Jennifer J., Aminian, Emily A., Wang, Kristin M., Shemesh, Avishai, Punzalan, Elman B., Sarma, Aartik, Calfee, Carolyn S., Christenson, Stephanie A., Langelier, Charles R., Hays, Steven R., Golden, Jeffrey A., Leard, Lorriana E., Kleinhenz, Mary Ellen, Kolaitis, Nicholas A., Shah, Rupal, Venado, Aida, Lanier, Lewis L., Greenland, John R., Sayah, David M., Ardehali, Abbas, Kukreja, Jasleen, Weigt, S. Samuel, Belperio, John A., Singer, Jonathan P., Looney, Mark R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869973/ https://www.ncbi.nlm.nih.gov/pubmed/36346670 http://dx.doi.org/10.1172/jci.insight.164603 |
Ejemplares similares
-
Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis
por: Santos, Jesse, et al.
Publicado: (2023) -
Short-Term Outcomes of Lung Transplantation for COVID-19 ARDS: A Single Center Experience
por: Nguyen, A., et al.
Publicado: (2022) -
COVID-19 Disease in Lung Transplant Recipients: A Case Series
por: Seijo, L.L., et al.
Publicado: (2021) -
Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice
por: Caudrillier, Axelle, et al.
Publicado: (2015) -
Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice
por: Mallavia, Beñat, et al.
Publicado: (2017)